Ropivacaine extended release - Encore/PainReform

Drug Profile

Ropivacaine extended release - Encore/PainReform

Alternative Names: ETI-211 - Encore; F-93; LNP-oily solution; LNP-oily solution (Ropivacaine); PRF-108

Latest Information Update: 06 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Encore Therapeutics
  • Class Amides; Local anaesthetics; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Postoperative pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2016 No development reported - Phase-I/II for Postoperative pain in Israel (SC)
  • 26 Sep 2011 Ropivacaine depot is available for licensing as of 26 Sep 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top